Arava Will Stay On The Market: FDA Denies Public Citizen Petition For Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis says FDA concluded the benefits of the rheumatoid arthritis therapy outweigh the safety risks. Public Citizen cited severe hepatic reactions and a lack of superiority over other therapies in requesting the drug be pulled.